Results 51 to 60 of about 3,200 (166)

Immunoscore—has it scored for colon cancer precision medicine? [PDF]

Annals of Translational Medicine, 2018
For patients with early-stage resectable colon cancer, the principal method for determining prognosis is based on histopathological characterization of the tumor, including the depth of tumor penetration (T stage) and spread to nearby lymph nodes (N stage), with the American Joint Committee on Cancer (AJCC) staging system perhaps the most widely used ...
Robert N, Jorissen, Anuratha, Sakthianandeswaren, Oliver M, Sieber   +2 more
openaire   +2 more sources

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer

Frontiers in Immunology, 2022
BackgroundThe immune microenvironment of tumors provides information on prognosis and prediction. A prior validation of the immunoscore for breast cancer (ISBC) was made on the basis of a systematic assessment of immune landscapes extrapolated from a ...
Xiaorui Han, Xiaorui Han, Wuteng Cao, Lei Wu, Lei Wu, Changhong Liang, Changhong Liang, Changhong Liang   +7 more
doaj   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source

Laryngeal Cancer Survival in Northern United Kingdom: A Multi‐Centre Retrospective Observational Study

Clinical Otolaryngology, EarlyView.
ABSTRACT Objectives Laryngeal cancer incidence has risen globally, yet survival outcomes have shown limited improvement over recent decades. This study evaluated contemporary outcomes across multiple centres in Northern UK and examined stage‐ and treatment‐specific survival. Design Multi‐centre retrospective observational study.
Amar Rajgor, Rhona Hurley, Catriona M. Douglas, Claire Paterson, James Moor, Shane Lester, Sara Sionis, Katherine Davies, James O’Hara, Gareth Inman, Terry Jones, David Winston Hamilton, Northern Head & Neck Alliance, Amarkumar Rajgor, Rhona Hurley, Catriona M. Douglas, Claire Paterson, James Moor, Shane Lester, Sara Sionis, Katherine Davies, James O'Hara, Gareth Inman, Terry Jones, David Winston Hamilton, Sarah Hill, Seamus O'Neill, Alison McLoughlin, Jemy Jose, Winson Wong, Michael Ho, Debbie Horne, Jarrod Homer, Matthew Kennedy, Emma Kinloch, Robert Metcalf, Iain Varley, Thomas Carroll, Sarah Healy, Helen Cocks, Michael Nugent, Leo Vassilou, Panos Kyzas, David Conway, John Greenman, Andrew Schache, Jason Fleming, Joanne Patterson, Keith Hunter, Paula Parvulescu, Rachel Brooker, Richard Shaw, Stephanie Meysner, Ola Rominiyi, Olena Mandrik   +54 more
wiley   +1 more source

Metabolic Profiling of Circulating and Tumour‐Infiltrating T Cells Uncovers Bioenergetic Checkpoints Linked With Immune and Clinical Skewing in Melanoma Patients

Immunology, EarlyView.
In this study, we revealed the disturbed metabolic status of circulating and tumour‐infiltrating CD4+ and CD8+ T cells in melanoma patients through targeted metabolomic and lipidomic (on sorted subsets) and at single cell level using the SCENITH method.
Hugo Brouque, Kareem Mahdy, Stephane Mouret, Sylvain Henry, Camille Niveau, Mélanie Cettour‐Cave, Martin Pelosse, Florence de Fraipont, Julie Charles, Andrei Turtoi, Philippe Saas, Caroline Aspord   +11 more
wiley   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Immunoscoring breast cancer: TILs remember what they target

Annals of Oncology, 2014
n ...
G. Curigliano, E. A. Perez
openaire   +3 more sources

An immunoscore nomogram for predicting survival in patients with oesophageal cancer

Aging, 2021
This study aimed to construct and validate an immunoscore nomogram that may be used to predict the prognosis of oesophageal cancer. With the gene expression data of oesophageal cancer in a public database, we used CIBERSORT to estimate the fractions of 22 infiltrating immune cell types.
Li, Gaoming, Song, Qiuyue, Cai, Angsong, Wei, Zeliang, Zhang, Rui, Yi, Dali, Chen, Jia, Li, Fang, Zhang, Yanqi, Liu, Ling, Wu, Yazhou, Yi, Dong   +11 more
openaire   +2 more sources

Closing the Translational Gap: Closed‐Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics

Cancer Medicine, Volume 15, Issue 8, August 2026.
Artificial intelligence accelerates cancer therapeutic development through an iterative, closed‐loop pipeline: from AI‐driven target and drug discovery, through automated synthesis and screening, to experimental validation in in vivo tumor models, culminating in clinical translation guided by patient data.
Tuğba Ören Varol, Mehmet Varol
wiley   +1 more source